3DPCT Combined With CT Guided RISI in the Treatment of Thoracic Malignant Tumors

Inclusion Criteria: * Pathological diagnosis of malignant tumor of chest, lesion diameter less than 7 cm. * There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by early treatment. * No bleeding tendency, anticoagulant therapy and / or antiplatelet coagulation drugs should be stopped for at least 1 week before treatment. * No serious or uncontrolled underlying diseases (such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction) are found. * There is a suitable puncture path, and the therapeutic dose is expected to be achieved. * KPS \> 70, expected to tolerate puncture / seed implantation, and expected survival time greater than 3 months. Exclusion Criteria: * Severe impairment of lung function (such as FEV1 \< 40% predicted value, FVC \< 50% predicted value, DLCO \< 40% predicted value). * High risk of skin invasion and ulceration at the puncture site before treatment. * There is a large range of liquefaction and necrosis in the lesion, and the expected seed distribution would be poor. * Pregnant women, lactating women and mentally ill patients. * The patient with poor compliance and unable to complete the treatment. * Other conditions of the researchers who think it is not suitable to participate in this clinical trial.